Q1 2025 Hikal Ltd Earnings Call Transcript
Key Points
- Increased market penetration and stable raw material prices in the current quarter.
- Significant rise in inquiries in the CDMO segment.
- Animal health facility completed validations for five products and initiated regulatory filings globally.
- Pharmaceutical business saw increased market demand and expanded customer base into new geographies.
- EBITDA growth of 16% year-on-year, reflecting improved operational efficiencies.
- Ongoing challenges and price pressure from competitors, particularly China, in the crop protection industry.
- Subdued demand in the crop protection business due to inventory correction and overcapacity.
- Increased depreciation and interest costs impacting profit before tax and profit after tax.
- Several CDMO project deliveries pushed back due to customer requirements.
- Interest costs increased due to capitalization of new assets, affecting profitability.
Ladies and gentlemen, good day, and welcome to Hikal Limited Q1 FY25 earnings conference call.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on date of this call. (Operators instructions)
Please note that this call being recorded. I now hand the conference over to Mr. Sameer Hiremath, Managing Director of Hikal Limited. Thank you, and over to you, sir.
Thank you. Ladies and gentlemen, good afternoon and a very warm welcome to all of you. We extend our gratitude to all of you for participating in our Q1 FY25 results conference call.
We are pleased to provide you with an update on the progress made by our company. We trust that you have had the opportunity to review our earnings release, investor presentation, and the financial statements for the quarter ended June 30, 2024. These documents can be accessed on both Hikal's website and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
